SciSparc SPRC
NASDAQ SPRC
$4.70 -0.01 (-0.11%)
As of: Sep 30, 2026 · 2:24 PM EDT

SciSparc (SPRC) Other financing activities (2016 - 2018)

Updated

SciSparc (SPRC) reported Other financing activities of $1.54 million for FY2025, down 25.8% from $2.08 million in FY2024.

Analysis

SciSparc (SPRC) Other financing activities (2016 - 2018) Analysis & Trends

Dating back to FY2015, SciSparc's Other financing activities record includes 11 years.

  • Other financing activities has declined for three consecutive years, though with a five-year compound annual growth rate of 12.1% (FY2020 to FY2025).
  • The FY2025 figure ranks as the lowest annual Other financing activities since FY2020.
  • According to Business Quant data, Other financing activities came in at $2.08 million in FY2024 (-41.9%), $3.57 million in FY2023 (-48.0%), $6.88 million in FY2022 (+253.3%) and $1.95 million in FY2021 (+123.7%).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 SciSparc 591,120.63 1.50 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2018 5.10 Mn
Jun 30, 2018 7.51 Mn
Mar 31, 2018 9.20 Mn
Sep 30, 2017 11.78 Mn
Jun 30, 2017 12.05 Mn
Mar 31, 2017 676,000.00
Sep 30, 2016 823,000.00
Jun 30, 2016 1.28 Mn
API Access

SciSparc Other financing activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-financing-activities&ticker=SPRC&period=max&api_key=YOUR_API_KEY